GlassScriptPhysician profile
Kourtney G Gardner
NPI 1194168666
$7,421.79
in general payments reported to CMS, 2019-2025
35 companies · $1,474 in 2025
The $1,474 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $341 · 2020: $499 · 2021: $1,005 · 2022: $1,255 · 2023: $1,519 · 2024: $1,329 · 2025: $1,474.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,166 · Education: $156.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,165.91 |
| Education | $155.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,139.47 | 2019-2025 | Tezspire, Fasenra, Breztri |
| Glaxosmithkline, LLC. | $1,026.21 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Csl Behring | $719.52 | 2019-2025 | Haegarda, Hizentra, Andembry |
| Regeneron Healthcare Solutions, INC. | $613.12 | 2019-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $602.45 | 2020-2025 | Takhzyro, Cuvitru, Hyqvia |
| Pharming Healthcare, INC. | $530.01 | 2019-2025 | Ruconest |
| Genentech USA, INC. | $331.89 | 2020-2025 | Xolair |
| Pfizer INC. | $221.75 | 2019-2025 | |
| Genzyme Corporation | $215.59 | 2021-2025 | |
| Octapharma USA, INC. | $211.63 | 2021-2025 | Panzyga, Cutaquig |
| Biocryst US Sales Co., LLC | $207.59 | 2021-2025 | Orladeyo |
| Novartis Pharmaceuticals Corporation | $184.45 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $146.24 | 2020-2023 | Airduo Digihaler |
| Grifols USA, LLC | $146.00 | 2022-2025 | Xembify, Prolastin-C Liquid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $134.40 | 2019-2023 | Spiriva Respimat |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $124.71 | 2019-2023 | Auvi-Q |
| Optinose US, INC. | $120.15 | 2021-2024 | |
| Horizon Therapeutics Plc | $102.81 | 2020-2022 | |
| Blueprint Medicines Corporation | $84.41 | 2023-2024 | Ayvakit |
| Amgen INC. | $81.74 | 2023-2024 | Tezspire, Actimmune |
| Abbvie INC. | $75.63 | 2022-2024 | |
| Lilly USA, LLC | $56.79 | 2024-2025 | Ebglyss |
| Mylan Specialty L.P. | $53.91 | 2022-2023 | Yupelri |
| Shire North American Group INC | $36.56 | 2019 | |
| Verona Pharma, INC. | $34.49 | 2025 | Ohtuvayre |
| Adma Biomanufacturing LLC | $32.25 | 2021-2022 | |
| Aimmune Therapeutics, INC. | $29.09 | 2021-2022 | |
| Alk-Abello, INC | $27.92 | 2019-2021 | |
| Incyte Corporation | $27.85 | 2022 | |
| Cycle Pharmaceuticals INC | $27.40 | 2025 | Sajazir |
| Ionis Pharmaceuticals, INC. | $18.69 | 2025 | Dawnzera |
| Hikma Pharmaceuticals USA | $16.84 | 2023 | Ryaltris |
| Viatris Specialty LLC | $14.30 | 2025 | Yupelri |
| Phadia US INC. | $14.21 | 2023 | Immunocap |
| Biocryst Pharmaceuticals, INC. | $11.72 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kourtney Gardner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.